Placeholder

A Globally Focused Industry

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

There will be an overall shift in the pharmaceutical industry from a very Western-centric model to a global one. Disease areas that were once considered niche are now given priority and the more prevalent disease therapeutic areas in the mature markets have taken a backseat. Vaccines, biologics, over-the-counter (OTC) products, and generics are the principal revenue generators in the emerging markets, say experts from Frost & Sullivan.
While some experts say the United States and Europe continue to hold the greatest opportunities for research and development, there is increasing innovation from India and China that will also generate opportunity. These areas are expanding rapidly — China is predicted to become the third largest pharma market next year — and will drive new opportunities for many years to come. Frost & Sullivan experts say the Asia-Pacific…

Sidebar:
Global Trends
Most Important BRIC Countries
Emerging Market Strategic Direction
Pharmaceutical and Biotechnology ­Market: Revenue by Region
Sound Bites From The Field

Experts
Jay Bolling. CEO and President, Roska Healthcare Advertising, a full-service advertising agency with expertise in engaging prospects through communications that integrate data and insight-driven marketing and advertising solutions. For more information, visit roskahealthcare.com.
Nick Colucci. President and CEO, Publicis Healthcare Communications Group, a healthcare communications agency
network with 40 offices around the globe. For more information, visit publicishealthcare.com.
Phil Deschamps. President and CEO, GSW Worldwide, a provider of a ­comprehensive and wide array of services, including advertising, public relations, digital and closed-loop marketing, strategic insight, branding, communications planning, ­predictive modeling, market access strategies, media, and market research. For more ­information, visit gsw-w.com.
Mark A. Goldberg, M.D. Chief Operating Officer, Parexel International Corp., a global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology, and medical- device industries. For more information, visit parexel.com.
Max Jackson. CEO, EMEA & APAC, Sudler & ­Hennessey, a global healthcare marketing and communications organization. For more information, visit sudler.com.
Ken Kramer, Ph.D. Senior VP, Medical Director, Alpha & Omega Worldwide, part of The Core Nation,  a medical communications company. For more ­information, visit thecorenation.com.
Robert T. McNally, Ph.D. President and CEO, GeoVax, a biotechnology company developing human vaccines for diseases caused by HIV-1 and other infectious agents. For more information, visit geovax.com.
John M. Vann. Executive VP, Corporate ­Development, Chiltern, a full-service, global contract research organization with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas and contract staffing solutions. For more information, visit chiltern.com.

FEEDBACK